Perspectives from Biopharmaceutical Process Development
Diana Ritz currently leads the Biopharm Drug Substance Development department at GSK. The department is responsible for the development of cell culture and purification processes for the production of biopharmaceutical medicines, characterization of these processes to ensure their robustness, process transfer to clinical and commercial manufacturing sites, and authoring associated regulatory filings. Diana received her B.S. in Chemical Engineering from Penn State University and her Ph.D. in Chemical Engineering from MIT. After completing her Ph.D., Diana joined the Microbial and Cell Culture Development department at GSK where she held several roles of increasing responsibility in cell line development, new technology development, and mid-/late-phase cell culture process development. She also led a matrix team responsible for expanding GSK s process analytical technology (PAT) capability and co-chaired a cross-functional team that leads the definition and evolution of the biopharm manufacturing platform.
Bioengineering
OPEN TO: Public